US 11,938,180 B2
Poliovaccine
Andrew Macadam, South Mimms (GB)
Assigned to SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE, MINISTERIAL CORRESPONDENCE AND PUBLIC ENQUIRIES, DEPARTMENT OF HEALTH AND SOCIAL CARE, London (GB)
Appl. No. 16/478,453
Filed by Secretary of State for Health and Social Care, London (GB)
PCT Filed Jan. 17, 2018, PCT No. PCT/GB2018/050129
§ 371(c)(1), (2) Date Jul. 16, 2019,
PCT Pub. No. WO2018/134584, PCT Pub. Date Jul. 26, 2018.
Claims priority of application No. 1700825 (GB), filed on Jan. 17, 2017.
Prior Publication US 2019/0358315 A1, Nov. 28, 2019
Int. Cl. A61K 39/13 (2006.01); A61K 39/00 (2006.01); C12N 7/00 (2006.01)
CPC A61K 39/13 (2013.01) [C12N 7/00 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/53 (2013.01); C12N 2770/32623 (2013.01); C12N 2770/32634 (2013.01)] 11 Claims
OG exemplary drawing
 
1. A poliovirus-like particle (VLP) which comprises modifications relative to the poliovirus particle from which the VLP is derived which stabilise the VLP, wherein:
(a) the VLP is derived from a type 1 poliovirus and comprises the following mutations: R4018G, T2025A, D2057E, L3119M, Q3178L and H1248P;
(b) the VLP is derived from a type 2 poliovirus and comprises the following mutations: L3085F, Q3178L, T1041I, F1134L and Y1159F;
(c) the VLP is derived from a type 2 poliovirus and comprises the following mutations: I4057V, D2057A, Q3178L, V1107I, F1134L and V1183L; or
(d) the VLP is derived from a type 3 poliovirus and comprises the following mutations: T4067A, L20181, L2215M, D2241E, H3019Y, L3085F, T1105M and F1132L;
wherein the modifications relative to the poliovirus particle from which the VLP is derived stabilises the native-antigenic conformation of the poliovirus capsid.